Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry.
Stenner F, Rothschild SI, Betticher D, Caspar C, Morant R, Popescu R, Rauch D, Huber U, Zenhäusern R, Rentsch C, Cathomas R. Stenner F, et al. Among authors: caspar c. Clin Genitourin Cancer. 2017 Aug 24:S1558-7673(17)30244-6. doi: 10.1016/j.clgc.2017.08.003. Online ahead of print. Clin Genitourin Cancer. 2017. PMID: 28958629
Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16).
Ribi K, Thürlimann B, Schär C, Dietrich D, Cathomas R, Zürrer-Härdi U, von Briel T, Anchisi S, Bohanes P, Blum V, von Burg P, Mannhart M, Caspar CB, von Moos R, Mark M. Ribi K, et al. Among authors: caspar cb. BMC Cancer. 2021 Feb 19;21(1):182. doi: 10.1186/s12885-021-07903-8. BMC Cancer. 2021. PMID: 33607966 Free PMC article.
Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16).
Mark M, Thürlimann B, Ribi K, Schär C, Dietrich D, Cathomas R, Zürrer-Härdi U, von Briel T, Anchisi S, Bohanes P, Blum V, von Burg P, Mannhart M, Caspar CB, von Moos R. Mark M, et al. Among authors: caspar cb. J Bone Oncol. 2019 Dec 16;21:100273. doi: 10.1016/j.jbo.2019.100273. eCollection 2020 Apr. J Bone Oncol. 2019. PMID: 31970055 Free PMC article.
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK.
Borner M, Koeberle D, Von Moos R, Saletti P, Rauch D, Hess V, Trojan A, Helbling D, Pestalozzi B, Caspar C, Ruhstaller T, Roth A, Kappeler A, Dietrich D, Lanz D, Mingrone W; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Borner M, et al. Among authors: caspar c. Ann Oncol. 2008 Jul;19(7):1288-1292. doi: 10.1093/annonc/mdn058. Epub 2008 Mar 17. Ann Oncol. 2008. PMID: 18349029 Free article. Clinical Trial.
Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland.
Moccia AA, Aeppli S, Güsewell S, Bargetzi M, Caspar C, Brülisauer D, Ebnöther M, Fehr M, Fischer N, Ghilardi G, Krasniqi F, Lang N, Mey U, Mingrone W, Novak U, Pfleger C, Richter P, Rütti M, Schmidt A, Stenner F, Voegeli M, Zander T, Zucca E, Hitz F. Moccia AA, et al. Among authors: caspar c. Hematol Oncol. 2021 Apr;39(2):196-204. doi: 10.1002/hon.2830. Epub 2020 Dec 23. Hematol Oncol. 2021. PMID: 33300135
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03).
Pesce GA, Klingbiel D, Ribi K, Zouhair A, von Moos R, Schlaeppi M, Caspar CB, Fischer N, Anchisi S, Peters S, Cathomas R, Bernhard J, Kotrubczik NM, D'Addario G, Pilop C, Weber DC, Bodis S, Pless M, Mayer M, Stupp R. Pesce GA, et al. Among authors: caspar cb. Eur J Cancer. 2012 Feb;48(3):377-84. doi: 10.1016/j.ejca.2011.10.016. Epub 2011 Nov 15. Eur J Cancer. 2012. PMID: 22093943 Clinical Trial.
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
Stahel RA, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Zippelius A, Mordasini C, Caspar CB, Eckhardt K, Schmid RA, Aebersold DM, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Ciernik IF, Weder W. Stahel RA, et al. Among authors: caspar cb. Lancet Oncol. 2015 Dec;16(16):1651-8. doi: 10.1016/S1470-2045(15)00208-9. Epub 2015 Nov 2. Lancet Oncol. 2015. PMID: 26538423 Clinical Trial.
Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14].
Hasler-Strub U, Mueller A, Li Q, Thuerlimann B, Ribi K, Gerber S, von Moos R, Fehr M, Rochlitz C, Zaman K, Aebi S, Hochstrasser A, Gick U, Baertschi D, Greuter S, Schreiber A, Caspar CB, Trojan A, Condorelli R, Ruhstaller T; Swiss Group for Clinical Cancer Research (SAKK). Hasler-Strub U, et al. Among authors: caspar cb. J Geriatr Oncol. 2023 Jan;14(1):101372. doi: 10.1016/j.jgo.2022.09.001. Epub 2022 Sep 18. J Geriatr Oncol. 2023. PMID: 36127284 Free article. Clinical Trial.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators; International Breast Cancer Study Group. Pagani O, et al. N Engl J Med. 2014 Jul 10;371(2):107-18. doi: 10.1056/NEJMoa1404037. Epub 2014 Jun 1. N Engl J Med. 2014. PMID: 24881463 Free PMC article. Clinical Trial.
Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
Schwotzer R, Manz MG, Pederiva S, Waibel C, Caspar C, Lerch E, Flammer AJ, Brouwers S, Seeger H, Heimgartner R, Fehr T, Rossi D, Bianchi E, Stüssi G, Ghilardi G, Gerber B. Schwotzer R, et al. Among authors: caspar c. Hematol Oncol. 2019 Dec;37(5):595-600. doi: 10.1002/hon.2677. Epub 2019 Nov 6. Hematol Oncol. 2019. PMID: 31486522
45 results